Drug Trial Radar · NCT06525389
Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST)
Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
428
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Sep 1, 2030
Study completion Sep 1, 2031
Sponsor
- Lead sponsor
- Duke UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute of Allergy and Infectious Diseases (NIAID); Pham Ngoc Thach University of Medicine; Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam; National Hospital for Tropical Diseases, Hanoi, Vietnam; Bach Mai Hospital; Gilead Sciences; Viatris Inc.
- First posted
- Jul 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
LAmB-FAST is a factorial randomized controlled trial simultaneously testing two interventions in one trial. LAmB-FAST seeks to inform treatment guidelines on the induction and maintenance therapy of HIV-associated talaromycosis (formerly called penicilliosis) and will answer the following three questions: 1. Is induction therapy using a single 10 mg\\/kg dose of liposomal amphotericin B (LAmB) is more effective than 14 days of the conventional deoxycholate amphotericin B (DAmB)? 2. Is adding flucytosine (5FC) to amphotericin B more effective than amphotericin B alone? 3. Is HIV viral load guided stopping of itraconazole maintenance therapy as effective as the current CD4 guided strategy in the prevention of talaromycosis relapse?
Conditions
- Talaromycosis
Interventions
Liposomal Amphotericin B (LAmB)Drug
Antifungal dosed at 10 mg/kg/day IV x one single dose.
Flucytosine (5FC)Drug
Antifungal dosed at 25mg/kg oral 3x daily.
Flucytosine (5FC) placebo pillDrug
Similar in appearance to flucytosine. Also dosed at 25mg/kg oral 3x daily.
Deoxycholate Amphotericin B (DAmB)Drug
Antifungal dosed at 0.7 mg/kg/day IV x 2 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time from enrollment to a composite of poor outcomesTime frame: up to 24 weeks
Locations
5 sites in 2 countries. Site status is shown where the registry gives one.
Duke University Medical Center
Durham, North Carolina
Bach Mai Hospital
Hanoi, Vietnam
National Hospital for Tropical Diseases
Hanoi, Vietnam
Hospital for Tropical Diseases
Ho Chi Minh City, Vietnam
Pham Ngoc Thach University of Medicine
Ho Chi Minh City, Vietnam
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.